Payment overview · 2025
General Payments
$383.05
18 reported records · 7 companies
Healthcare provider profile · identity verified
Jim George, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORNEY, TX · NPI 1619288230
Verified facts
What the public records show
CMS Open Payments records show Jim George, M.D. received $383.05 in general payments during 2025 across 18 reported records.
Abbott Laboratories accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $155.02 | 40.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.21 | 15.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.42 | 12.6% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $43.37 | 11.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.62 | 10.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.27 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.14 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.05 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $155.02 | 7 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.44 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 483 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 121 |
| Lisinopril | Lisinopril | 293 | 98 |
| Metformin Hcl | Metformin Hcl | 268 | 96 |
| Losartan Potassium | Losartan Potassium | 250 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 70 |
| Omeprazole | Omeprazole | 212 | 80 |
| Gabapentin | Gabapentin | 202 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 64 |
| Prednisone | Prednisone | 162 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 53 |
| Furosemide | Furosemide | 144 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 44 |
| Alprazolam | Alprazolam | 124 | 25 |
| Potassium Chloride | Potassium Chloride | 120 | 35 |
| Simvastatin | Simvastatin | 110 | 40 |
| Finasteride | Finasteride | 109 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 43 |
| Montelukast Sodium | Montelukast Sodium | 98 | 35 |
| Ozempic | Semaglutide | 97 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 30 |
| Sertraline Hcl | Sertraline Hcl | 95 | 28 |
| Allopurinol | Allopurinol | 93 | 29 |
| Glimepiride | Glimepiride | 93 | 28 |
| Clonazepam | Clonazepam | 86 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 23 |
| Metformin Hcl Er | Metformin Hcl | 80 | 25 |
| Carvedilol | Carvedilol | 79 | 32 |
| Meloxicam | Meloxicam | 77 | 32 |
| Azithromycin | Azithromycin | 75 | 59 |
| Alendronate Sodium | Alendronate Sodium | 72 | 29 |
| Celecoxib | Celecoxib | 70 | 32 |
| Methocarbamol | Methocarbamol | 70 | 40 |
| Trazodone Hcl | Trazodone Hcl | 67 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 24 |
| Memantine Hcl | Memantine Hcl | 60 | 20 |
| Atenolol | Atenolol | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 22 |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Donepezil Hcl | Donepezil Hcl | 46 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Spironolactone | Spironolactone | 45 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 18 |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 43 | 35 |
| Lovastatin | Lovastatin | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 19 |
| Glipizide | Glipizide | 42 | 15 |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 13 |
| Eliquis | Apixaban | 38 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 11 |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | 16 |
| Fenofibrate | Fenofibrate | 35 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Famotidine | Famotidine | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 11 |
| Mupirocin | Mupirocin | 27 | 23 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Naproxen | Naproxen | 23 | 12 |
| Nystatin | Nystatin | 23 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Temazepam | Temazepam | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Ramipril | Ramipril | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Torsemide | Torsemide | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.05 · 18 records | Abbott Laboratories | ABRYSVO, ACCRUFER, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, KRYSTEXXA, Korlym, NURTEC ODT, Ozempic, PREVNAR 20, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error